Previous Close | 10.67 |
Open | 10.68 |
Bid | 10.72 x 900 |
Ask | 10.97 x 900 |
Day's Range | 10.31 - 11.04 |
52 Week Range | 6.82 - 21.50 |
Volume | |
Avg. Volume | 43,785 |
Market Cap | 140.945M |
Beta (5Y Monthly) | 3.49 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.63 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 38.00 |
Key Insights Significant control over Greenwich LifeSciences by retail investors implies that the general public has...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Even if it's not a huge purchase, we think it was good to see that Snehal Patel, the CEO, CFO & Director of Greenwich...
STAFFORD, Texas, December 29, 2022--Greenwich LifeSciences Provides Year End Update
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
STAFFORD, Texas, December 01, 2022--Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
If you want to know who really controls Greenwich LifeSciences, Inc. ( NASDAQ:GLSI ), then you'll have to look at the...
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
STAFFORD, Texas, August 11, 2022--Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
STAFFORD, Texas, August 03, 2022--Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
STAFFORD, Texas, July 28, 2022--Greenwich LifeSciences Provides Financing Strategy & Corporate Update
STAFFORD, Texas, July 12, 2022--Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
STAFFORD, Texas, July 11, 2022--Greenwich LifeSciences Announces Suspension of Share Repurchase Program